切换至 "中华医学电子期刊资源库"
高级检索
中华实验和临床感染病杂志(电子版)

中华实验和临床感染病杂志(电子版) ›› 2017, Vol. 11 ›› Issue (02) : 168 -171. doi: 10.3877/cma.j.issn.1674-1358.2017.02.013

临床论著

广州地区丙型肝炎患者肌苷三磷酸酶基因多态性与利巴韦林所致贫血的相关性
邓浩辉1, 许敏1, 李晓强1, 雷春亮1,†()   
  1. 1. 510060　广州市，广东省广州市第八人民医院肝病科
  • 收稿日期:2016-02-27 出版日期:2017-04-15
  • 通信作者: 雷春亮
  • 基金资助:
    广州市医药卫生科技项目(No. 20141A010033)

Correlation of inosine triphosphate pyrophosphatase single nucleotide polymorphism and ribavirin-related anemia in patients with chronic hepatitis C in Guangzhou

Haohui Deng1, Min Xu1, Xiaoqiang Li1, Chunliang Lei1,†()   

  1. 1. Department of Liver Diseases, Guangzhou the Eighth People’s Hospital, Guangzhou 510060, China
  • Received:2016-02-27 Published:2017-04-15
  • Corresponding author: Chunliang Lei
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

邓浩辉, 许敏, 李晓强, 雷春亮. 广州地区丙型肝炎患者肌苷三磷酸酶基因多态性与利巴韦林所致贫血的相关性[J/OL]. 中华实验和临床感染病杂志(电子版), 2017, 11(02): 168-171.

Haohui Deng, Min Xu, Xiaoqiang Li, Chunliang Lei. Correlation of inosine triphosphate pyrophosphatase single nucleotide polymorphism and ribavirin-related anemia in patients with chronic hepatitis C in Guangzhou[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(02): 168-171.

目的

探讨慢性丙型肝炎患者肌苷三磷酸（ITPA）单核苷酸基因多态性（SNP）与治疗过程中利巴韦林相关溶血性贫血发生的相关性。

方法

收集本院2012年3月至2015年9月收治的使用聚乙二醇化干扰素（PegIFN）联合利巴韦林抗病毒治疗的慢性丙型肝炎患者的全血标本，采用直接测序法检测ITPA rs1127354、rs7270101和20号染色体连锁的rs6051702位点的SNP，并收集患者抗病毒治疗后第4、12、24、36、48周血红蛋白（Hb）数据和药物调整情况，使用独立样本t检验、卡方检验、重复测量和多变量方差分析比较不同位点SNP和利巴韦林相关贫血、药物调整的关系。

结果

本研究共纳入85例丙型肝炎患者，其中78例患者完成48周抗病毒治疗并有完整的随访资料。85例患者中ITPA rs1127354位点CC型61例（71.8%），AC型21例（24.7%），AA型3例（3.5%）；rs7270101位点85例均为AA型（100%）；20号染色体rs6051702位点CC型2例（2.3%），AC型22例（25.9%），AA型61例（71.8%），其中7例未完成治疗的患者rs1127354位点均为CC型，rs6051702位点均为AA型。完成48周抗病毒治疗的78例患者中，rs1127354位点AC和AA型有4例（16.7%）患者在治疗过程中需调整利巴韦林剂量，24例（44.4%）CC型患者需调整利巴韦林剂量，差异有统计学意义（χ2 = 5.571、P = 0.018）；rs6051702位点的SNP与药物剂量调整无显著相关性（χ2 = 1.789、P = 0.182）。rs1127354位点AC型和AA型患者治疗第4周、12周、24周血红蛋白下降水平显著低于CC型患者（P均< 0.05）。

结论

广州地区ITPA rs7270101位点不存在SNP，rs1127354位点AA型和AC型对利巴韦林相关贫血有保护作用，对该位点SNP检测有利于指导临床医生个体化用药。

关键词: 肝炎, 丙型, 慢性, 肌苷三磷酸酶, 利巴韦林, 贫血
Objective

To investigate inosine triphosphate pyrophosphatase (ITPA) single nucleotide polymorphism (SNP) in patients with hepatitis C in Guangzhou and the correlation of ribavirin-related anemia during 48 weeks antiviral therapy.

Methods

The blood sample of hepatitis C patients treated with polyethylene glycol interferon (PegIFN) and ribavirin (RBV) were collected to detect SNP of ITPA rs1127354, rs7270101 and rs6051702 on chromosome 20 by direct sequencing method, and the data of hemoglobin (Hb) at 4, 12, 24, 36 and 48 weeks during treatment were collected and analyzed by independent-samples t test, χ2 test, repeated measures and multivariate ANOVA.

Results

Total of 85 patients with hepatitis C were enrolled, including 78 patients with hepatitis C who finished the 48 weeks treatment. Among the 85 patients with hepatitis C, genotyping of ITPA rs1127354 showed that 3 patients (3.5%) were homozygous for AA, 21 patients (24.7%) were heterozygous for AC, 61 patients (71.8%) were homozygous for CC. All the 85 patients were homozygous for AA in ITPA rs7270101. Two patients (2.3%) in rs6051702 on chromosome 20 were homozygous for CC, 22 patients (25.9%) were heterozygous for AC, 61 patients (71.8%) were homozygous for CC. Four patients (16.7%) in rs1127354 AA and AC needed to reduce the dose of ribavirin during the treatmet, however, the chance of reducing the dose of ribavirin was much higher in rs1127354 CC genotype (χ2 = 5.571, P = 0.018), and rs6051702 genotypes were not significantly related to dose reduction of ribavirin (χ2 = 1.789, P = 0.182). Anemia in rs1127354 CC genotype was more frequent than AA and AC genotypes at 4, 12 and 24 weeks during treatment (P all < 0.05).

Conclusions

ITPA rs7270101 SNP doesn’t among hepatitis C patients in Guangzhou. The rs1127354 AC/AA genotypes were protective factor for ribavirin related anemia.

Key words: Hepatitis C, Inosine triphosphate pyrophosphatase, Ribavirin, Anemia
表1 ITPA和20号染色体连锁的SNP位点的引物序列
SNP位点 上游引物（F） 下游引物（R）
rs1127354 5'-AAGAGATAGAGAAGCAAGGA-3' 5'-CTGGACAAGAAGAGCAAGT-3'
rs7270101 5'-GAAGAGATAGAGAAGCAAGGA-3' 5'-CTGGACAAGAAGAGCAAGT-3'
rs6051702 5'-GGTATCTAGCTGATACTTGG-3' 5'-CCTGTGAATTTTACTTCTGT-3'
表2 85例丙型肝炎患者ITPA rs1127354、rs7270101和20号染色体连锁rs6051702位点的基因多态性[例（%）]
SNP位点 CC型 AC型 AA型 Hardy-Weinberg检验（χ2值） P值
rs1127354 61（71.8） 21（24.7） 3（3.5） 0.4828 0.4871
rs6051702 2（2.3） 22（25.9） 61（71.8） 0.0001 0.9921
rs7270101 0（0.0） 0（0.0） 85（100.0） — —
表3 78例患者48周治疗过程中rs1127354和rs6051702位点各时间点血红蛋白下降水平（±s，g/dl）
治疗时间 rs1127354 rs6051702
CC型（n = 54） AC/AA型（n = 24） F值 P值 AA型（n = 54） AC/CC型（n = 24） F值 P值
4周 1.81±1.60 0.56±1.02 11.401 0.001 1.56±1.80 1.45±1.19 0.047 0.830
12周 3.30±1.68 2.43±1.41 4.395 0.040 3.21±1.68 2.79±1.81 0.674 0.415
24周 3.68±1.75 2.76±1.54 4.459 0.038 3.67±1.70 2.72±2.06 3.136 0.082
36周 3.38±1.87 3.14±1.96 0.241 0.625 3.27±1.67 4.53±4.24 2.612 0.112
48周 1.68±2.24 2.58±2.20 2.423 0.124 2.67±2.97 2.76±3.40 0.008 0.930
1
中华医学会肝病学分会，中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版)[J/CD]. 中国肝脏病杂志(电子版),2015,7(3):19-35.
2
王茉莉，潘煜，姜晶, 等. ITPA基因变异与干扰素联合利巴韦林治疗过程中发生贫血的相关性[J]. 中国老年学杂志,2013,33(12):2759-2761.
3
Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction[J]. Gastroenterology,2010,139(4):1181-1189.
4
Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C[J]. Nature,2010,464(7287):405-408.
5
Kurosaki M, Tanaka Y, Tanaka K, et al. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin[J]. Antiviral Therapy,2011,16(5):685-694.
6
Ochi H, Maekawa T, Abe H, et al. ITPA Polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients[J]. Gastroenterology,2010,139(4):1190-1197.
7
Kim JS, Ahn SM, Jung YK, et al. The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean[J]. J Korean Med Sci,2013,28(8):1213-1219.
8
Zhang X, Cai Q, Hong C, et al. Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1[J]. J Med Virol,2013,85(7):1163-1169.
9
Wu LS, Jimmerson LC, Macbrayne CE, et al. Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus[J]. CPT Pharmacometrics Syst Pharmacol,2016,5(2):65-73.
10
闫改勤，庞婷，邢卉春, 等. 2014年EASL丙型肝炎治疗推荐意见解读[J/CD]. 中华实验和临床感染病杂志(电子版),2015,9(3):299-304.
11
成军. 慢性丙型肝炎治疗的过去,现在和未来[J/CD]. 中华实验和临床感染病杂志(电子版),2015,9(1):4-5.
12
EASL Clinical Practice Guidelines: management of hepatitis C virus infection[J]. J Hepatol,2014,60(2):392-420.
13
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J]. Hepatology,2015,62(3):932-954.
14
Lim SG, Dan YY. A 2015 roadmap for the management of hepatitis C virus infections in Asia[J]. Korean J Intern Med,2015,30(4):423-433.
15
Mensing S, Polepally AR, Konig D, et al. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir, and ribavirin in patients with hepatitis C virus genotype 1 infection: combined analysis from 9 phase 1b/2 studies[J]. AAPS J,2016,18(1):270-280.
16
Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, et al. Efficacy of second generation direct-acting antiviral agents for treatment naive hepatitis C genotype 1: a systematic review and network Meta-analysis[J]. PLoS One,2015,10(12):e145953.
17
谢尧. 中国慢性丙型肝炎抗病毒治疗DAA时代与PegIFN/RBV标准治疗[J/CD]. 中国肝脏病杂志(电子版),2015,7(3):40-41.
18
Tahata Y, Hiramatsu N, Oze T, et al. The impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy[J]. J Med Virol,2016,88(10):1776-1784.
19
Asselah T, Zeuzem S, Soriano V, et al. ITPA Genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection[J]. PLoS One,2015,10(12):e144004.
20
About F, Oudot-Mellakh T, Niay J, et al. Impact of IL-28B, APOH and ITPA polymorphisms on efficacy and safety of TVR- or BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20-CUPIC study[J]. PLoS One,2015,10(12):e145105.
21
魏阳，史昌河，闫杰. IL-28B基因多态性在丙型病毒性肝炎中的临床意义[J/CD]. 中华实验和临床感染病杂志(电子版),2014,8(6):856-859.
22
Zhang YY, Chen HB, Xu Y, et al. Interferon-λ-related genes and therapeutic response in Chinese hepatitis C patients[J]. World J Gastroenterol,2015,21(13):4006-4013.
23
El-Bendary M, Neamatallah M A, Abd E M, et al. Interleukin 28B polymorphism predicts treatment outcome among Egyptian patients infected with HCV genotype 4[J]. Hepatogastroenterology,2015,62(140):947-950.
24
Honda M, Kaneko S. IL-28B genetic variation and hepatic ISGs expression predict treatment efficacy of IFN-based anti-viral therapy for chronic hepatitis C[J]. Nihon Rinsho,2015,73(Suppl 9):178-183.
25
Maan R, van der Meer AJ, Brouwer WP, et al. ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection[J]. PLoS One,2015,10(10):e139317.
[1] 唐小清, 何萍, 杨友, 罗霞, 张菊英, 杨鑫, 余进洪. 声触诊弹性成像联合脉冲多普勒超声成像参数与早期慢性肾脏病分期的相关性及临床价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(05): 491-499.
[2] 周涵, 武胡雯, 张培深, 邓晗彬, 范闻轩, 李嘉诚, 程少文. 蛋白质组学在慢性难愈合创面研究中的应用进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 536-540.
[3] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[4] 张龙, 孙善柯, 徐伟, 李文柱, 李俊达, 池涌泉, 何广胜, 成峰, 王学浩, 饶建华. 腹腔镜脾切除治疗血液系统疾病的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 870-875.
[5] 程柏凯, 杨光. 高胰岛素-正葡萄糖钳夹技术评估慢性肾脏病患者胰岛素抵抗的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 334-339.
[6] 陈意志. 核磁共振钆造影剂导致的肾源性系统性纤维化[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 358-358.
[7] 王贝贝, 崔振义, 王静, 王晗妍, 吕红芝, 李秀婷. 老年股骨粗隆间骨折患者术后贫血预测模型的构建与验证[J/OL]. 中华老年骨科与康复电子杂志, 2024, 10(06): 355-362.
[8] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[9] 唐诗, 薛传优, 叶兴, 张鸿举, 戴瑞. 急性病毒性肝炎患者血脂、血糖、蛋白、尿酸变化特点及其与预后的关联[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 396-399.
[10] 杨卫东, 周威, 向洪涛. 慢性萎缩性胃炎患者幽门螺杆菌感染与炎性细胞因子及病理特征的关系[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 459-464.
[11] 李润东, 豆小文, 张秀明. 失笑散联合胃复春治疗慢性萎缩性胃炎的疗效及对血清免疫受体和炎症因子水平的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 470-473.
[12] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[13] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[14] 闫维, 张二明, 张克, 安欣华, 向平超. 北京市石景山区40岁及以上居民早期慢性阻塞性肺疾病异质性及影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 533-540.
[15] 黄圣楷, 许斌, 苏健, 孙龙. 海南省2010~2020年乙型肝炎流行趋势的时间序列分析及预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 555-561.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号